Literature DB >> 27291567

Sflt-1 in heart failure: relation with disease severity and biomarkers.

Damien Gruson1,2, Michel P Hermans1, Benjamin Ferracin1, Sylvie A Ahn3, Michel F Rousseau3.   

Abstract

Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP (ρ = 0.37, p < 0.01), soluble ST2 (ρ = 0.52, p < 0.01), Galectin-3 (ρ = 0.38, p < 0.01), aldosterone (ρ = 0.25, p = 0.01) and PTH(1-84) (ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.

Entities:  

Keywords:  Aldosterone; BNP; Galectin-3; ST2; heart failure; prognosis sFlt-1

Mesh:

Substances:

Year:  2016        PMID: 27291567     DOI: 10.1080/00365513.2016.1190863

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study.

Authors:  Cecilia Berardi; David A Bluemke; Brian A Houston; Todd M Kolb; João A Lima; Theo Pezel; Ryan J Tedford; Samuel G Rayner; Richard K Cheng; Peter J Leary
Journal:  J Heart Lung Transplant       Date:  2022-01-10       Impact factor: 13.569

2.  MZe786 Rescues Cardiac Mitochondrial Activity in High sFlt-1 and Low HO-1 Environment.

Authors:  Lissette Carolina Sanchez-Aranguren; Homira Rezai; Shakil Ahmad; Faisal A Alzahrani; Anna Sparatore; Keqing Wang; Asif Ahmed
Journal:  Antioxidants (Basel)       Date:  2020-07-09

Review 3.  Preeclampsia and Related Cardiovascular Risk: Common Genetic Background.

Authors:  Michalina Lisowska; Tadeusz Pietrucha; Agata Sakowicz
Journal:  Curr Hypertens Rep       Date:  2018-07-03       Impact factor: 5.369

4.  Mirror syndrome with noncompaction cardiomyopathy in the mother and fetus. Case report

Authors:  Jesús Arnulfo Velásquez-Penagos; Ana María Flórez-Ríos; Edison Muñoz-Ortiz; Jairo Alfonso Gándara-Ricardo; Juan Pablo Flórez-Muñoz; Erika Holguín-González
Journal:  Rev Colomb Obstet Ginecol       Date:  2021-09-30

5.  Soluble Flt-1 in AMI Patients Serum Inhibits Angiogenesis of Endothelial Progenitor Cells by Suppressing Akt and Erk's Activity.

Authors:  Lijie Zhang; Xingkun Zhang; Xiaoming Zhong; Mengya Fan; Guoliang Wang; Wei Shi; Ran Xie; Yinxiang Wei; Hailong Zhang; Xiangxu Meng; Yaohui Wang; Yuanfang Ma
Journal:  Biology (Basel)       Date:  2022-08-09

6.  Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.

Authors:  Nasser Davarzani; Sandra Sanders-van Wijk; Micha T Maeder; Peter Rickenbacher; Evgueni Smirnov; Joël Karel; Thomas Suter; Rudolf A de Boer; Dirk Block; Vinzent Rolny; Christian Zaugg; Matthias E Pfisterer; Ralf Peeters; Hans-Peter Brunner-La Rocca
Journal:  EPMA J       Date:  2018-05-13       Impact factor: 6.543

7.  Prenatal biochemical screening and long term risk of maternal cardiovascular disease: population based cohort study.

Authors:  Joel G Ray; Tianhua Huang; Wendy S Meschino; Eyal Cohen; Alison L Park
Journal:  BMJ       Date:  2018-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.